Single-center, non-commercial phase 2 clinical trial to evaluate 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment using locoregional teleradiotherapy and hormone therapy
Giving a written informed consent
Histopathologically confirmed high or very high risk prostate cancer
Completion of radical locoregional treatment
Completion of locoregional treatment within 3 months before inclusion to the study
The presence of distant metastases confirmed by radiological examination
Absence of approval to use effective contraception method
Absence of Patient's consent to participate in the Study
Urinary tract obstruction or/and hydronephrosis.